Inozyme Other Assets vs Other Current Liab Analysis

INZY Stock

USD 5.54 0.39 7.57%

Inozyme Pharma financial indicator trend analysis is infinitely more than just investigating Inozyme Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inozyme Pharma is a good investment. Please check the relationship between Inozyme Pharma Other Assets and its Other Current Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Other Assets vs Other Current Liab

Other Assets vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inozyme Pharma Other Assets account and Other Current Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Inozyme Pharma's Other Assets and Other Current Liab is 0.62. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Inozyme Pharma, assuming nothing else is changed. The correlation between historical values of Inozyme Pharma's Other Assets and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Inozyme Pharma are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Other Assets i.e., Inozyme Pharma's Other Assets and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Other Assets

Other Current Liab

Most indicators from Inozyme Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.Selling General Administrative is likely to drop to about 14.5 M in 2024. Issuance Of Capital Stock is likely to drop to about 63.3 M in 2024

	2021	2022	2023	2024 (projected)
Interest Income	211K	1.9M	4.1M	4.3M
Net Interest Income	211K	1.9M	4.1M	4.3M

Interest Income Net Interest Income

Inozyme Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital
Total Assets		0.97	0.95	0.98	0.97	0.85	-0.05	-0.88	0.74	0.42	0.8	0.85	0.78	1.0	0.78	0.89	1.0	-0.73	0.94	0.9	0.83	-0.63	0.87	0.99	1.0	1.0
Other Current Liab	0.97		0.96	0.93	0.92	0.88	0.16	-0.93	0.64	0.19	0.68	0.81	0.62	0.96	0.79	0.93	0.98	-0.67	0.94	0.92	0.85	-0.56	0.89	0.96	0.98	0.97
Total Current Liabilities	0.95	0.96		0.95	0.94	0.94	0.12	-0.93	0.75	0.2	0.73	0.9	0.63	0.94	0.71	0.91	0.95	-0.78	0.96	0.88	0.87	-0.68	0.88	0.95	0.95	0.94
Total Stockholder Equity	0.98	0.93	0.95		1.0	0.91	-0.16	-0.83	0.85	0.48	0.88	0.93	0.83	0.97	0.67	0.81	0.97	-0.86	0.93	0.84	0.77	-0.79	0.82	0.99	0.96	0.96
Net Tangible Assets	0.97	0.92	0.94	1.0		0.91	-0.18	-0.81	0.86	0.49	0.89	0.93	0.83	0.97	0.63	0.8	0.97	-0.87	0.91	0.82	0.75	-0.79	0.82	0.99	0.96	0.95
Property Plant And Equipment Net	0.85	0.88	0.94	0.91	0.91		0.03	-0.81	0.86	0.2	0.77	0.96	0.64	0.84	0.53	0.72	0.86	-0.9	0.89	0.78	0.73	-0.83	0.81	0.88	0.84	0.83
Net Debt	-0.05	0.16	0.12	-0.16	-0.18	0.03		-0.38	-0.42	-0.88	-0.54	-0.19	-0.61	-0.06	0.32	0.32	-0.03	0.29	0.17	0.28	0.41	0.35	0.02	-0.08	0.0	-0.01
Retained Earnings	-0.88	-0.93	-0.93	-0.83	-0.81	-0.81	-0.38		-0.57	-0.03	-0.55	-0.74	-0.48	-0.88	-0.89	-0.93	-0.89	0.6	-0.97	-0.97	-0.98	0.49	-0.8	-0.86	-0.9	-0.89
Accounts Payable	0.74	0.64	0.75	0.85	0.86	0.86	-0.42	-0.57		0.6	0.95	0.96	0.86	0.73	0.35	0.44	0.73	-0.96	0.74	0.58	0.5	-0.95	0.64	0.78	0.7	0.69
Cash	0.42	0.19	0.2	0.48	0.49	0.2	-0.88	-0.03	0.6		0.77	0.42	0.87	0.43	0.15	0.05	0.39	-0.46	0.23	0.16	0.0	-0.49	0.26	0.42	0.37	0.39
Non Current Assets Total	0.8	0.68	0.73	0.88	0.89	0.77	-0.54	-0.55	0.95	0.77		0.89	0.97	0.8	0.45	0.47	0.79	-0.88	0.73	0.61	0.48	-0.86	0.68	0.83	0.77	0.77
Non Currrent Assets Other	0.85	0.81	0.9	0.93	0.93	0.96	-0.19	-0.74	0.96	0.42	0.89		0.78	0.84	0.48	0.65	0.85	-0.95	0.86	0.72	0.67	-0.9	0.77	0.88	0.83	0.81
Other Assets	0.78	0.62	0.63	0.83	0.83	0.64	-0.61	-0.48	0.86	0.87	0.97	0.78		0.78	0.49	0.44	0.76	-0.76	0.66	0.58	0.42	-0.74	0.63	0.79	0.74	0.75
Cash And Short Term Investments	1.0	0.96	0.94	0.97	0.97	0.84	-0.06	-0.88	0.73	0.43	0.8	0.84	0.78		0.79	0.89	1.0	-0.72	0.94	0.9	0.82	-0.62	0.87	0.99	1.0	1.0
Net Receivables	0.78	0.79	0.71	0.67	0.63	0.53	0.32	-0.89	0.35	0.15	0.45	0.48	0.49	0.79		0.81	0.78	-0.33	0.84	0.94	0.87	-0.23	0.69	0.72	0.8	0.81
Common Stock Shares Outstanding	0.89	0.93	0.91	0.81	0.8	0.72	0.32	-0.93	0.44	0.05	0.47	0.65	0.44	0.89	0.81		0.9	-0.49	0.89	0.88	0.91	-0.36	0.78	0.87	0.92	0.91
Short Term Investments	1.0	0.98	0.95	0.97	0.97	0.86	-0.03	-0.89	0.73	0.39	0.79	0.85	0.76	1.0	0.78	0.9		-0.73	0.94	0.9	0.82	-0.63	0.89	0.99	1.0	1.0
Non Current Liabilities Total	-0.73	-0.67	-0.78	-0.86	-0.87	-0.9	0.29	0.6	-0.96	-0.46	-0.88	-0.95	-0.76	-0.72	-0.33	-0.49	-0.73		-0.76	-0.6	-0.57	0.99	-0.56	-0.8	-0.7	-0.69
Capital Surpluse	0.94	0.94	0.96	0.93	0.91	0.89	0.17	-0.97	0.74	0.23	0.73	0.86	0.66	0.94	0.84	0.89	0.94	-0.76		0.97	0.94	-0.67	0.82	0.94	0.94	0.94
Other Current Assets	0.9	0.92	0.88	0.84	0.82	0.78	0.28	-0.97	0.58	0.16	0.61	0.72	0.58	0.9	0.94	0.88	0.9	-0.6	0.97		0.95	-0.51	0.77	0.88	0.91	0.91
Other Stockholder Equity	0.83	0.85	0.87	0.77	0.75	0.73	0.41	-0.98	0.5	0.0	0.48	0.67	0.42	0.82	0.87	0.91	0.82	-0.57	0.94	0.95		-0.47	0.66	0.81	0.84	0.84
Total Liab	-0.63	-0.56	-0.68	-0.79	-0.79	-0.83	0.35	0.49	-0.95	-0.49	-0.86	-0.9	-0.74	-0.62	-0.23	-0.36	-0.63	0.99	-0.67	-0.51	-0.47		-0.44	-0.71	-0.6	-0.59
Deferred Long Term Liab	0.87	0.89	0.88	0.82	0.82	0.81	0.02	-0.8	0.64	0.26	0.68	0.77	0.63	0.87	0.69	0.78	0.89	-0.56	0.82	0.77	0.66	-0.44		0.84	0.87	0.87
Net Invested Capital	0.99	0.96	0.95	0.99	0.99	0.88	-0.08	-0.86	0.78	0.42	0.83	0.88	0.79	0.99	0.72	0.87	0.99	-0.8	0.94	0.88	0.81	-0.71	0.84		0.99	0.99
Total Current Assets	1.0	0.98	0.95	0.96	0.96	0.84	0.0	-0.9	0.7	0.37	0.77	0.83	0.74	1.0	0.8	0.92	1.0	-0.7	0.94	0.91	0.84	-0.6	0.87	0.99		1.0
Net Working Capital	1.0	0.97	0.94	0.96	0.95	0.83	-0.01	-0.89	0.69	0.39	0.77	0.81	0.75	1.0	0.81	0.91	1.0	-0.69	0.94	0.91	0.84	-0.59	0.87	0.99	1.0

Click cells to compare fundamentals

Inozyme Pharma Account Relationship Matchups

Inozyme Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	47.9M	169.4M	123.5M	139.2M	200.8M	132.8M
Other Current Liab	2.3M	6.9M	8.5M	7.5M	12.6M	7.2M
Total Current Liabilities	3.2M	10.0M	11.6M	14.7M	14.7M	10.4M
Total Stockholder Equity	(33.2M)	158.1M	109.3M	118.6M	140.5M	87.9M
Net Tangible Assets	(33.2M)	158.1M	109.3M	118.4M	136.2M	74.5M
Property Plant And Equipment Net	298K	2.6M	4.4M	3.6M	2.6M	2.5M
Net Debt	(31.6M)	(158.6M)	(19.9M)	(26.1M)	12.0M	12.6M
Retained Earnings	(34.7M)	(91.1M)	(147.7M)	(214.8M)	(285.9M)	(271.6M)
Accounts Payable	901K	3.1M	2.4M	2.5M	1.2M	2.0M
Cash	31.6M	159.9M	23.3M	32.9M	34.6M	42.4M
Non Current Assets Total	484K	18.4M	8.2M	7.8M	4.6M	7.3M
Non Currrent Assets Other	56K	3.5M	3.4M	3.8M	1.7M	2.3M
Cash And Short Term Investments	47.1M	159.9M	111.8M	127.9M	188.6M	124.4M
Net Receivables	104K	155K	62K	115K	385K	404.3K
Common Stock Shares Outstanding	15.2M	23.4M	23.6M	37.8M	51.8M	30.6M
Short Term Investments	15.5M	119.7M	88.5M	95.0M	154.0M	88.0M
Liabilities And Stockholders Equity	47.9M	169.4M	123.5M	139.4M	200.8M	132.8M
Non Current Liabilities Total	77.9M	1.3M	2.6M	6.1M	45.7M	25.2M
Capital Surpluse	1.4M	249.2M	256.9M	333.4M	383.4M	402.5M
Other Current Assets	224K	3.3M	3.5M	3.5M	7.3M	7.6M
Other Stockholder Equity	(76.5M)	79.8M	133.4M	333.6M	426.4M	447.7M
Total Liab	81.2M	11.3M	14.3M	20.8M	60.4M	32.7M
Net Invested Capital	(33.2M)	158.1M	109.3M	122.5M	185.2M	96.8M
Total Current Assets	47.5M	151.0M	115.3M	131.4M	196.3M	125.5M
Accumulated Other Comprehensive Income	5K	2K	18K	(205K)	41K	43.1K
Net Working Capital	44.2M	141.0M	103.7M	116.7M	181.6M	115.1M
Property Plant Equipment	298K	2.6M	4.4M	2.0M	2.3M	2.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
F	Ford Motor
CRM	Salesforce

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inozyme Other Assets vs Other Current Liab Analysis

Other Assets vs Other Current Liab

Other Assets vs Other Current Liab Correlation Analysis

Correlation Coefficient

Other Assets

Other Current Liab

Inozyme Pharma fundamental ratios Correlations

Inozyme Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inozyme Pharma fundamental ratios Accounts

Also Currently Popular

Additional Tools for Inozyme Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 0.98	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings
Capital Surpluse	- 0.97	Retained Earnings
Non Current Liabilities Total	- 0.96	Accounts Payable
Non Current Liabilities Total	- 0.95	Non Currrent Assets Other
Total Liab	- 0.95	Accounts Payable